Medi-Promotions announces launch of Medi-Scripts PLUS
CHICAGO Medi-Promotions, the originator of Medi-Scripts prescription pads, announced the launch of its next generation prescription pad model called Medi-Scripts PLUS, the company said Monday.
Medi-Scripts PLUS takes the prescribers’ prescription pads one step further by including patient offers, such as vouchers, temporary stored-value/loyalty cards, coupons and rebates from pharmaceutical sponsors. This new model is aimed directly at initiating new patient starts for a therapy.
The Medi-Scripts PLUS pilot program, which launched Monday, will provide 2,000 pilot recipients with the new prescription pads in early 2008. The initial pilot will be a three-month program delivered to 2,000 prescribers based on a subset of brand targets.
A recent survey of 176 primary care physicians found that 91 percent currently distribute coupons and vouchers. Another survey of 100 physicians found that physicians are more likely to distribute a coupon or voucher if attached to a prescription. “Our promotional products provide pharmaceutical manufacturers with an alternative sampling opportunity for all phases of their products’ lifecycles,” said Richard Zwickel, vice president of Medi-Scripts PLUS.
Wyeth hit with $134.5 million in Nevada lawsuit
RENO, Nev. Wyeth has been ordered by a Washoe county court to pay more than $43 million each to three northern Nevada women who claimed that the company’s hormone replacement drugs, Prempro and Premarin caused their breast cancer, according to the Reno Gazette-Journal.
The jury said the drugs were defective and found the company negligent for producing, manufacturing and selling them. The jurors awarded $7.5 million to each woman in past damages and $36 million-$40 million in future damages.
The jurors still have to decide whether the company is liable for punitive damages. Wyeth is also fighting about 5,300 similar lawsuits involving 7,800 women in state and federal courts across the country.
Teva sues Apotex over Coreg infringement
TRENTON, N.J. Teva has sued Apotex to prevent it from selling a generic version of the heart medication Coreg, according to Bloomberg.
The two companies, as well as other generic drug makers, received approval from the Food and Drug Administration to sell a generic version on Sept. 5. Teva says it owns four patents that cover various forms and processes to make the generic, carvedilol. The company also said that Apotex might have to buy the compound made using the patented process in order to sell the generic.
The lawsuit was filed yesterday in a federal court in New Jersey. Coreg had sales of $853.8 million in the first six months of 2007.